GenTrust LLC Purchases Shares of 1,438 Johnson & Johnson (NYSE:JNJ)

GenTrust LLC purchased a new stake in shares of Johnson & Johnson (NYSE:JNJ) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 1,438 shares of the company’s stock, valued at approximately $208,000.

Several other large investors have also added to or reduced their stakes in the company. Heritage Investors Management Corp lifted its holdings in Johnson & Johnson by 2.2% during the fourth quarter. Heritage Investors Management Corp now owns 177,029 shares of the company’s stock valued at $25,602,000 after purchasing an additional 3,806 shares in the last quarter. Whipplewood Advisors LLC purchased a new position in Johnson & Johnson during the fourth quarter valued at approximately $225,000. NewEdge Wealth LLC lifted its holdings in Johnson & Johnson by 8.3% during the fourth quarter. NewEdge Wealth LLC now owns 203,057 shares of the company’s stock valued at $29,366,000 after purchasing an additional 15,503 shares in the last quarter. Magnolia Private Wealth LLC bought a new stake in shares of Johnson & Johnson during the fourth quarter valued at approximately $202,000. Finally, Nelson Capital Management LLC raised its position in shares of Johnson & Johnson by 10.9% during the fourth quarter. Nelson Capital Management LLC now owns 6,124 shares of the company’s stock valued at $886,000 after buying an additional 601 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Insider Activity

In related news, Director Mark A. Weinberger bought 1,000 shares of the stock in a transaction dated Thursday, December 12th. The stock was purchased at an average cost of $147.22 per share, with a total value of $147,220.00. Following the completion of the purchase, the director now owns 1,000 shares of the company’s stock, valued at $147,220. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Timothy Schmid sold 403 shares of the business’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the sale, the executive vice president now directly owns 15,098 shares of the company’s stock, valued at $2,357,552.70. This represents a 2.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the stock. Citigroup reduced their price objective on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a research report on Wednesday, December 11th. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 25th. Wells Fargo & Company reduced their price objective on shares of Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating on the stock in a research report on Thursday, January 23rd. Leerink Partners reduced their price objective on shares of Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating on the stock in a research report on Thursday, January 23rd. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $181.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, February 19th. Nine analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $170.67.

Johnson & Johnson Trading Up 0.9 %

JNJ stock opened at $165.23 on Friday. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $168.85. The stock has a market capitalization of $397.81 billion, a price-to-earnings ratio of 24.85, a price-to-earnings-growth ratio of 2.56 and a beta of 0.52. The firm’s fifty day simple moving average is $150.90 and its two-hundred day simple moving average is $156.06.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The business had revenue of $22.52 billion for the quarter, compared to analysts’ expectations of $22.44 billion. During the same quarter in the previous year, the business posted $2.29 earnings per share. The business’s revenue was up 5.3% compared to the same quarter last year. As a group, analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.00%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is currently 74.59%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.